Search - tctmd.com

Displaying 341 - 360 of 691

Sort: Relevancy | Date

News Features

Subtherapeutic Heparin: As Stories Multiply, Concerns Mount

Yael L. Maxwell

November 27, 2019

News Conference News AHA 2019

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

Shelley Wood

November 16, 2019

News Conference News AHA 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

Michael O'Riordan

November 14, 2019

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Shelley Wood

November 11, 2019

News Daily News

For Percutaneous LVADs, Vascular Complications Decreasing but Still Common

Caitlin E. Cox

November 06, 2019

News Daily News

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Michael O'Riordan

November 05, 2019

News Daily News

Repeat Target-Lesion PCI: An Option for Public Reporting?

Michael O'Riordan

October 25, 2019

News Conference News AHA 2019

ISCHEMIA Countdown Begins, but a ‘Black-and-White’ Answer Is Uncertain

Shelley Wood

October 25, 2019

News Daily News

Risk Prediction Model Personalizes Revascularization Options for FREEDOM-Like Patients

Michael O'Riordan

October 17, 2019

News Conference News TCT 2019

NCSI Strategy for Acute MI Cardiogenic Shock Reaps Better Survival

Caitlin E. Cox

October 10, 2019

News Conference News

Former EXCEL Investigator Alleges Trial Manipulation, Prompting Vehement Denials

Michael O'Riordan

October 07, 2019

News Conference News TCT 2019

EXCEL at 5 Years: PCI for Left Main CAD Still Noninferior to CABG

Marcus A. Banks

September 28, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Michael O'Riordan

September 24, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

News Daily News

Post-MI Mechanical Complications Infrequent but Deadly

Todd Neale

September 16, 2019

News Conference News ESC 2019

TRANSIENT: Treatment Timing Inconsequential When STEMI Resolves Before Revascularization

L.A. McKeown

September 09, 2019

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31997-X/fulltext

News Conference News ESC 2019

Ten-Year SYNTAXES Results Fix Roles for CABG, PCI in Complex CAD

Shelley Wood

September 05, 2019

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

Todd Neale

September 02, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

Advertisement

Subtherapeutic Heparin: As Stories Multiply, Concerns Mount

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

For Percutaneous LVADs, Vascular Complications Decreasing but Still Common

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Repeat Target-Lesion PCI: An Option for Public Reporting?

ISCHEMIA Countdown Begins, but a ‘Black-and-White’ Answer Is Uncertain

Risk Prediction Model Personalizes Revascularization Options for FREEDOM-Like Patients

NCSI Strategy for Acute MI Cardiogenic Shock Reaps Better Survival

Former EXCEL Investigator Alleges Trial Manipulation, Prompting Vehement Denials

EXCEL at 5 Years: PCI for Left Main CAD Still Noninferior to CABG

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Post-MI Mechanical Complications Infrequent but Deadly

TRANSIENT: Treatment Timing Inconsequential When STEMI Resolves Before Revascularization

Ten-Year SYNTAXES Results Fix Roles for CABG, PCI in Complex CAD

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content